Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2021

View Archived Issues

Bristol Myers Squibb identifies new Toll-like receptor 7 agonists

Mindset Pharma discloses 5-HT2A receptor agonists

Merck & Co. and The Walter and Eliza Hall Institute of Medical Research divulge new antimalarials

Gasherbrum Bio presents new GLP-1 receptor agonists

LX-9211: development of an AAK1 inhibitor for neuropathic pain

Study may lead to new pulmonary fibrosis treatments

CELMoD CC-99282 for hematological malignancies

TH-1902, a new docetaxel-peptide conjugate with efficacy in SORT1-positive TNBC models

Pan-caspase inhibitor shows in vivo efficacy against MRSA and other bacterial skin infections

Novel quinuclidine modulator of cellular progranulin shows promising ADME-PK properties

Homozygous missense variant in PTPN2 gene tied to early-onset Crohn's disease

Innovent Biologics and Bolt Biotherapeutics collaborate to develop ISAC candidates

Insilico Medicine to use 4B Technologies' AI technology in drug discovery for neurological diseases

Preclinical data support role of idronoxil as anti-inflammatory for early-stage COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...